BAQSIMI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6938798 | AMPHASTAR PHARMS INC | Fluid or powdery product dispensing device |
Jan, 2022
(2 years ago) | |
| US10213487 | AMPHASTAR PHARMS INC | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(11 years from now) | |
| US10894133 | AMPHASTAR PHARMS INC | Device for dispensing a fluid product |
Jan, 2038
(13 years from now) | |
| US10765602 | AMPHASTAR PHARMS INC | Medication delivery systems and methods |
Sep, 2039
(15 years from now) | |
Baqsimi is owned by Amphastar Pharms Inc.
Baqsimi contains Glucagon.
Baqsimi has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Baqsimi are:
- US6938798
Baqsimi was authorised for market use on 24 July, 2019.
Baqsimi is available in powder;nasal dosage forms.
Baqsimi can be used as treatment of severe hypoglycemia in patients with diabetes.
The generics of Baqsimi are possible to be released after 23 September, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
More Information on Dosage
BAQSIMI family patents
